ASX:CSLBiotechs
The Bull Case For CSL (ASX:CSL) Could Change Following Canadian HEMGENIX Reimbursement Milestone – Learn Why
CSL recently reported that its first Canadian patient has received HEMGENIX® for hemophilia B at London Health Sciences Centre, following public reimbursement agreements that now provide access in Ontario and British Columbia while other provinces review coverage.
This early real-world use of HEMGENIX® under public funding in Canada highlights how CSL’s high-value gene therapy portfolio is beginning to translate into tangible patient access and market uptake.
Next, we’ll examine how this...